ASCO: New antibody-drug conjugate shows promising safety and...
Blastic plasmacytoid dendric cell neoplasm (BPDCN) is a rare, aggressive blood cancer that often involves the bone marrow, skin and,...
NK cells complexed with bispecific antibody yield high...
HOUSTON ― A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a...
ASH: Triplet combination regimens demonstrate high response...
ABSTRACTS: 216, 219, 1011
SAN DIEGO ― Three clinical trials led by researchers from The University of Texas MD Anderson...
ASH: Monoclonal antibody therapy improves survival in...
ABSTRACT: 805
SAN DIEGO – Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH) – a...
Novel CAR T cell therapy obe-cel demonstrates high response...
Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel anti-CD19...
MD Anderson launches Institute for Cell Therapy Discovery &...
The University of Texas MD Anderson Cancer Center today announced the launch of its Institute for Cell Therapy Discovery &...
Novel triplet regimen yields promising response in...
According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or...
ESMO: Combination therapy reduced agitated delirium in...
ABSTRACT: 1476O
BARCELONA, Spain ― Treatment with a combination of haloperidol and lorazepam reduced symptoms of agitated delirium,...
NK cells expressing interleukin-21 show promising antitumor...
Natural killer (NK) cells engineered to express interleukin-21 (IL-21) demonstrated sustained antitumor activity against glioblastoma...
CAR NK cells with CD28 costimulation improved cell...
Adding CD28 costimulation to cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cells targeting CD70+ cancers...